British-Swedish drugs giant Astrazeneca, led by boss Pascal Soriot (pictured), is buying the rare diseases specialist as part of plans to expand into new lucrative areas of treatment.
British-Swedish drugs giant Astrazeneca, led by boss Pascal Soriot (pictured), is buying the rare diseases specialist as part of plans to expand into new lucrative areas of treatment.